Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Pavord ID, Williams M, Weatherall M; Novel START Study Team.
N Engl J Med. 2019 May 23;380(21):2020-2030. doi: 10.1056/NEJMoa1901963. Epub 2019 May 19.
Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial.
Chipps BE, Israel E, Beasley R, Panettieri RA Jr, Albers FC, Rees R, Dunsire L, Danilewicz A, Johnsson E, Cappelletti C, Papi A.
Chest. 2023 Sep;164(3):585-595. doi: 10.1016/j.chest.2023.03.035. Epub 2023 Mar 30.
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, Mane S, Vohlidkova A, Martindale J, Williams M, Shirtcliffe P, Holliday M, Weatherall M, Beasley R; PRACTICAL study team.
Lancet. 2019 Sep 14;394(10202):919-928. doi: 10.1016/S0140-6736(19)31948-8. Epub 2019 Aug 23.
Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth.
Axelsson I, Naumburg E, Prietsch SO, Zhang L.
Cochrane Database Syst Rev. 2019 Jun 10;6(6):CD010126. doi: 10.1002/14651858.CD010126.pub2.
Identifying and managing bronchiolitis.
Paluch L.
JAAPA. 2020 Sep;33(9):12-15. doi: 10.1097/01.JAA.0000694944.22382.39.
Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases.
Ren H, Yu X, Li M, Luo Z, Lin Y, Meng Y, Cheng Q, Wei T.
Nano Lett. 2025 Sep 17;25(37):13802-13810. doi: 10.1021/acs.nanolett.5c03184. Epub 2025 Sep 8.
2019 Year in Review: Aerosol Therapy.
Berlinski A.
Respir Care. 2020 May;65(5):705-712. doi: 10.4187/respcare.07738.
Efficacy of Inhaler Devices in New-Onset Mild Asthma: A Randomized Blinded Multicenter Trial.
Zhou Y, Li N, Zheng Q, Han W, Zhou L, Zhao H, Liu X, Bao W, Pan Y, Zhang Y, Lv C, Cao H, Li D, Ge C, Zhu H, Zhu S, Shen H, Zhang M.
Adv Ther. 2025 Aug;42(8):3861-3881. doi: 10.1007/s12325-025-03263-y. Epub 2025 Jun 11.
Dry Powder Inhalers: From Bench to Bedside.
Chrystyn H, Azouz W, Tarsin W.
J Aerosol Med Pulm Drug Deliv. 2023 Dec;36(6):324-335. doi: 10.1089/jamp.2023.29103.hc. Epub 2023 Nov 28.
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, Calzetta L, Singh D, Spina D, Walker MJ, Page CP.
Lancet Respir Med. 2013 Nov;1(9):714-27. doi: 10.1016/S2213-2600(13)70187-5. Epub 2013 Oct 25.
